Piper Sandler initiated coverage of Cerevel Therapeutics with an Overweight rating and $33 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CERE:
- Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
- Insiders Buy the Dip in These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back — Here’s Why You Should Pay Attention
- Cerevel Therapeutics CEO buys $2.0M in common stock
- Cerevel Therapeutics price target lowered to $25 from $29 at Mizuho
- Cerevel Therapeutics downgraded to Neutral from Buy at BofA